NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026

contractFind a TenderRef ocds-h6vhtk-051a9dProcurement Act 2023SME suitablepending

Estimated value

Awarded value

£832.8m

Awarded 31 May 2026

Suppliers

33

5 SME

Lots

2

2 awarded

Published

09 Jun 2026

Description

NHS Branded Medicines Tranche B - Lot 1 - London & South of England - CM/PHR/25/5731 Period of Framework Agreement: 1 September 2026 to 31 August 2028 with an option or option(s) to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Lot 2 - Ustekinumab for North of England and Midlands & East, period of Framework Agreement: 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.

Scope

Reference
C414011
Commercial tool
Standalone contract
Contract dates
31 Aug 2026 to 31 Aug 2028
Possible extension to 31 Aug 2030

With an option or option(s) to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.

CPV classifications
33600000
Contract locations
North West England, United Kingdom
South East England, United Kingdom
South West England, United Kingdom
London, United Kingdom
East Midlands, United Kingdom
West Midlands, United Kingdom
North East England, United Kingdom
Particular suitability
Small and medium-sized enterprises (SME)

Award criteria

Criteria the buyer will use to evaluate bids.

NameDescriptionTypeWeighting
Price is not the only award criterionPrice is not the only award criterion and all criteria are stated only in the procurement documentsprice

Submission & procedure

Procedure
Open procedure

Award details· 2 awards

Awarded supplier(s), contract period and value as published in the award notice.

Awarded value

£813.9m

Award date

31 May 2026

Contract start

31 Aug 2026

Contract end

31 Aug 2028

Lots · 2 total

Divisions of the contract. Each lot can be awarded separately.

View all →
LotTitleEst. valueStatus
1Lot 1 - Tranche B for London & South of England£541.5mcomplete
2Lot 2 - Ustekinumab for North of England and Midlands & East£50.9mcomplete